Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002355 · ClinicalTrials.gov registry record · NA
A Comparison of ISIS 2922 Used Immediately or Later in Patients With Cytomegalovirus (CMV) of the Eyes
A NA study, sponsored by Ionis Pharmaceuticals.
- Completed
- Registry status
- NA
- Development phase
- 60
- Enrollment target
NCT00002355: Completed NA study, sponsored by Ionis Pharmaceuticals.
NCT00002355 is a NA study that has completed, run by Ionis Pharmaceuticals. The registered enrollment target is 60 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00002355, a NA study, has completed, sponsored by Ionis Pharmaceuticals.
- COMPLETED
- Registry status
- NA
- Development phase
- 60 participants
- Enrollment target
Study Summary
To determine a clinically safe and effective dose of intravitreally injected ISIS 2922 and to compare the safety and efficacy of immediate versus delayed treatment in AIDS patients with previously untreated, peripheral cytomegalovirus ( CMV ) retinitis.
Interventions
- DRUG Fomivirsen sodium
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Phase | NA |
What the finished NCT00002355 record still lists
NCT00002355 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 60 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower).
The record links to 0 conditions, and to 1 intervention - of which Fomivirsen sodium is the first listed.
NCT00002355 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00002355 about?
NCT00002355 is a clinical study titled "A Comparison of ISIS 2922 Used Immediately or Later in Patients With Cytomegalovirus (CMV) of the Eyes". To determine a clinically safe and effective dose of intravitreally injected ISIS 2922 and to compare the safety and efficacy of immediate versus delayed treatment in AIDS patients with previously untreated, peripheral cytomegalovirus ( CMV ) retinitis.
What is the current status of trial NCT00002355?
This trial is currently completed. It is a NA study. The enrollment target is 60 participants.
What interventions are being tested in trial NCT00002355?
The interventions under investigation include: Fomivirsen sodium (DRUG).
Who is sponsoring clinical trial NCT00002355?
This trial is sponsored by Ionis Pharmaceuticals, which has 76 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00002355's enrollment target sits among peer trials
60 1164th of 2000 higher than 745 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00576069 · 60 participants
Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma
- NCT01297400 · 60 participants · Phase 2
Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns
- NCT01734122 · 60 participants
Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor
- NCT01804634 · 60 participants · Phase 2
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors